This month saw publication of the results of a groundbreaking new trial into umbilical cord blood as a treatment for autism. The study showed enormous promise, with 75% of children showing an improvement in their condition.
The medical centre responsible; Duke University, have now announced another ground breaking trial looking at umbilical cord tissue.
Due to start in May 2017, the new study will determine the safety of intravenous infusions of human umbilical cord tissue derived mesencyhmal stem cells (MSC) in children with autism spectrum disorder.
Children participating in the study will receive up to three separate infusions two months apart at Duke University, North Carolina with results published in 2019.
Stem cell treatments for autism
Duke has a long established record using cord blood to treat to neurological conditions, such as autism, cerebral palsy and stroke, however, this is the first time an academic centre in the USA has registered a trial of this nature using stem cells from cord tissue.
Cord blood and cord tissue trials – autism
- NCT03099239 – hCT-MSCs for Children With Autism Spectrum Disorder (ASD)
- NCT02192749 – Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
- NCT02176317 – Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
- NCT01638819 – Autologous Cord Blood Stem Cells for Autism
- NCT01343511 – Safety and Efficacy of Stem Cell Therapy in Patients With Autism